<div id="readability-page-1"><p><span>Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report)</span> had its price objective reduced by equities research analysts at Chardan Capital  from $9.00 to $8.00 in a report released on Friday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Chardan Capital's target price would indicate a potential upside of 488.24% from the stock's previous close.</p><p>Other equities research analysts also recently issued reports about the company. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Tenaya Therapeutics in a report on Wednesday, October 8th. HC Wainwright  reiterated a &#34;buy&#34; rating and issued a $5.00 price objective on shares of Tenaya Therapeutics in a research report on Tuesday, September 2nd. Four investment analysts have rated the stock with a Buy rating and one  has issued  a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $6.00.</p><div><p><span></span><span>Get <strong>Tenaya Therapeutics</strong> alerts:</span></p></div><p><b>Get Our Latest Stock Analysis on TNYA</b></p><h2>Tenaya Therapeutics Price Performance</h2><p>Tenaya Therapeutics stock opened at $1.36 on Friday. The firm has a market capitalization of $226.45 million, a price-to-earnings ratio of -1.74 and a beta of 3.13. The company's 50 day simple moving average is $1.51 and its 200 day simple moving average is $1.11. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $3.69. </p><p>Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.03.  As a group, analysts predict that  Tenaya Therapeutics will post -1.35 EPS for the current fiscal year. </p><h2>Institutional Investors Weigh In On Tenaya Therapeutics</h2><p>Several institutional investors have recently bought and sold shares of the company. Scientech Research LLC acquired a new position in  Tenaya Therapeutics during the 3rd quarter worth approximately $27,000.  DAFNA Capital Management LLC bought a new stake in shares of  Tenaya Therapeutics in the first quarter worth $27,000.  Mirador Capital Partners LP boosted its holdings in  Tenaya Therapeutics by 38.2% during the third quarter. Mirador Capital Partners LP now owns 23,500 shares of the company's stock worth $38,000 after purchasing an additional 6,500 shares during the last quarter.  Callan Family Office LLC bought a new position in  Tenaya Therapeutics in the first quarter valued at $50,000.  Finally, Comerica Bank acquired a new stake in  Tenaya Therapeutics in the 1st quarter valued at $50,000. Institutional investors own  90.54% of the company's stock. </p><h2>Tenaya Therapeutics Company Profile</h2> (Get Free Report)<p>Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Tenaya Therapeutics</li><li>What is the MACD Indicator and How to Use it in Your Trading</li><li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li><li>3 Natural Gas Stocks That Offer Great Dividend Yields</li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>How to Use High Beta Stocks to Maximize Your Investing Profits</li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ZQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ZQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Tenaya Therapeutics Right Now?</h2><p>Before you consider Tenaya Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.</p><p>While Tenaya Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TNYA

<p>Chardan Capital has lowered its price target for Tenaya Therapeutics (NASDAQ:TNYA) from $9.00 to $8.00, maintaining a "buy" rating. The stock has a potential upside of 488.24% from its previous close. Other analysts have mixed ratings, with a consensus "Moderate Buy" and a price target of $6.00. Tenaya Therapeutics is a biotechnology company focused on heart disease therapies, with several products in clinical trials.</p>

Chardan Capital Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $8.00